A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma

Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 5, 1997, Pages 438-442

  Pappo, Alberto S ^a,b   Bowman, Laura C ^a,b   Furman, Wayne L ^a,b   Rao, Bhaskar N ^a   Kun, Larry E ^a   Jenkins, Jesse J ^a   Crom, William R ^a   Luo, Xiaolong ^a   Kaste, Sue C ^a   Avery, Loraine ^a   Meyer, William H ^a,b   Shapiro, David N ^a,b   Crist, William M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Methotrexate; Rhabdomyosarcoma

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; IFOSFAMIDE; MESNA; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADOLESCENT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

EID: 0031423784     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199709000-00006     Document Type: Article

References (25)

1. Pappo AS, Shapiro DN, Crist WM, et al. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995;13:2123-39.
2. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. Cancer 1988;61:209-20.
3. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-30.
4. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71:1904-22.
5. Koscielniak E, Rodary C, Flamant F, et al. Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective european multi-center analysis. Med Pediatr Oncol 1992;20:209-14.
6. Raney B, Crist W, Maurer H, et al. Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response: a report from the Intergroup Rhabdomyosarcoma Study I. Cancer 1983;52:44-50.
7. Pappo AS, Etcubanas E, Santana V, et al. A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. Cancer 1993;71:2119-25.
8. Horowitz M, Etcubanas E, Christensen M, et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol 1988;6:308-14.
9. Pui C. Childhood leukemias. N Eng J Med 1995;332:1618-30.
10. Meyer W, Malawer M. Osteosarcoma. Clinical features and evolving surgical and chemotherapeutic strategies. Fed Clin North Amer 1991;38:317.
11. Bode U. Methotrexate as relapse therapy for rhabdomyosarcoma. J Pediatr Hematol Oncol 1986;8:70-2.
12. Pratt C, Roberts D, Shanks E, et al. Clinical trials and pharmacokinetics of intemittent high-dose methotrexate-"leucovorin rescue" for children with malignant tumors. Cancer Res 1974;34:3326-31.
13. Bode U, Erps M, Schiffer D. 42-hour methotrexate infusions as relapse therapy for childhood malignancies: toxicity and efficacy of 109 infusions. Pediatr Hematol Oncol 1987;4:15-24.
14. Isacoff W, Eilber F, Tabbarah H, et al. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue. Cancer Treat Rep 1978;62:1295-304.
15. Selawry O, Holland J, Wolman I. Effect of vincristine (NSC-67574) on malignant solid tumors in children. Cancer Chemother Rep 1968;52:497-500.
16. Sutow W. Vincristine (NSC-67574) therapy for malignant solid tumors in children (except Wilms tumor). Cancer Chemother Rep 1968;52:485-7.
17. Shaw R, Moore E, Mueller P, et al. The effect of actinomycin D on childhood neoplasms. Am J Dis Child 1960;99:96-103.
18. Haddy T, Nora A, Sutow W, et al. Cyclophosphamide treatment for metastatic soft tissue sarcoma. Am J Dis Child 1967;114:301-8.
19. Sutow W. Cyclophosphamide (NSC-26271) in Wilms tumor and rhabdomyosarcoma. Cancer Chemother Rep 1967;51:407-9.
20. Tan C, Dargeon H, Burchenal J. The effect of actinomycin D on cancer in childhood. Pediatrics 1959;544-61.
21. Jaffe N, Paed D. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972;30:1627-31.
22. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Crist WM, Garnsey L, Beltangady MS, et al. Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II. J Clin Oncol 1990;8:443-52.
24. Vietti T, Crist W, Ruby E, et al. Topotecan window in patients with rhabdomyosarcoma (RMS): an IRSG study. Proc Amer Soc Clin Oncol 1997;16:510a (abstract).
25. O'Bryan R, Luce J, Talley R, et al. Phase II evaluation of adriamycin in human neoplasia. Cancer 1973;32:1-6.